Results 1 to 10 of about 7,431,159 (264)

The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug–Drug Interactions: Drug–Gene, Drug–Gene–Gene and Drug–Drug–Gene Interactions [PDF]

Pharmaceuticals, 2021
Drug interactions are a well-known cause of adverse drug events, and drug interaction databases can help the clinician to recognize and avoid such interactions and their adverse events. However, not every interaction leads to an adverse drug event.
Martina Hahn, Sibylle C. Roll
doaj   +5 more sources

The Prevalence of Potential Drug-Drug-Gene Interactions: A Descriptive Study Using Swiss Claims Data [PDF]

Pharmacogenomics and Personalized Medicine
Nina L Wittwer,1,2 Christoph R Meier,1– 3 Carola A Huber,4 Julie D Moser,1 Henriette E Meyer zu Schwabedissen,5 Samuel S Allemann,6,* Cornelia Schneider1,2,* 1Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology,
Wittwer NL, Meier CR, Huber CA, Moser JD, Meyer zu Schwabedissen HE, Allemann SS, Schneider C   +6 more
doaj   +6 more sources

Drug-Drug-Gene Interactions in Cardiovascular Medicine. [PDF]

Pharmgenomics Pers Med, 2022
Cardiovascular disease remains a leading cause of both morbidity and mortality worldwide. It is widely accepted that both concomitant medications (drug–drug interactions, DDIs) and genomic factors (drug–gene interactions, DGIs) can influence ...
Asiimwe IG, Pirmohamed M.
europepmc   +5 more sources

Estimating the incidence of actionable drug-gene interactions in Japanese patients with major depressive disorder [PDF]

Frontiers in Psychiatry
BackgroundAlthough several guidelines provide dosing recommendations for antidepressants based on patients’ genetic information, pharmacogenetic testing for antidepressant use is rarely routinely performed in Japan.
Masakazu Hatano, Masashi Ikeda, Takeo Saito, Masami Miyata, Nakao Iwata, Shigeki Yamada   +5 more
doaj   +3 more sources

Drug Repurposing Using Modularity Clustering in Drug-Drug Similarity Networks Based on Drug–Gene Interactions [PDF]

Pharmaceutics, 2021
Drug repurposing is a valuable alternative to traditional drug design based on the assumption that medicines have multiple functions. Computer-based techniques use ever-growing drug databases to uncover new drug repurposing hints, which require further ...
Vlad Groza, Mihai Udrescu, Alexandru Bozdog, Lucreţia Udrescu   +3 more
doaj   +3 more sources

An inductive learning-based method for predicting drug-gene interactions using a multi-relational drug-disease-gene graph [PDF]

Journal of Pharmaceutical Analysis
Computational analysis can accurately detect drug-gene interactions (DGIs) cost-effectively. However, transductive learning models are the hotspot to reveal the promising performance for unknown DGIs (both drugs and genes are present in the training ...
Jian He, Yanling Wu, Linxi Yuan, Jiangguo Qiu, Menglong Li, Xuemei Pu, Yanzhi Guo   +6 more
doaj   +3 more sources

Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment. [PDF]

Cell Genom, 2022
Pancreatic cancer (PDAC) is a highly aggressive malignancy for which the identification of novel therapies is urgently needed. Here, we establish a human PDAC organoid biobank from 31 genetically distinct lines, covering a representative range of tumor ...
Hirt CK, Booij TH, Grob L, Simmler P, Toussaint NC, Keller D, Taube D, Ludwig V, Goryachkin A, Pauli C, Lenggenhager D, Stekhoven DJ, Stirnimann CU, Endhardt K, Ringnalda F, Villiger L, Siebenhüner A, Karkampouna S, De Menna M, Beshay J, Klett H, Kruithof-de Julio M, Schüler J, Schwank G.   +23 more
europepmc   +5 more sources

Drug-gene interactions in older patients with coronary artery disease [PDF]

BMC Geriatrics
Background Older patients with coronary artery disease (CAD) are particularly vulnerable to the efficacy and adverse drug reactions, and may therefore particularly benefit from personalized medication.
Shizhao Zhang, Chao Lv, Lisha Dong, Yangxun Wu, Tong Yin   +4 more
doaj   +3 more sources

A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine [PDF]

Pharmaceutics, 2020
Physiologically-based pharmacokinetic (PBPK) modeling is a well-recognized method for quantitatively predicting the effect of intrinsic/extrinsic factors on drug exposure.
Tobias Kanacher, Andreas Lindauer, Enrica Mezzalana, Ingrid Michon, Celine Veau, Jose David Gómez Mantilla, Valerie Nock, Angèle Fleury   +7 more
doaj   +3 more sources

Primary Care Prescription Drug Use and Related Actionable Drug‐Gene Interactions in the Danish Population [PDF]

Clinical and Translational Science, 2020
Pharmacogenetics (PGx) aims to improve drug therapy using the individual patients’ genetic make‐up. Little is known about the potential impact of PGx on the population level, possibly hindering implementation of PGx in clinical care.
Carin Adriana Theodora Catharina Lunenburg, Alexander Sebastian Hauser, Kazi Ishtiak‐Ahmed, Christiane Gasse   +3 more
doaj   +3 more sources